Claude

People & Governance

Centene earns a B- governance grade: a capable but lightly tenured CEO navigating the company's worst operational crisis since its founding, supported by a refreshed and independent board, but undermined by a securities fraud class action, a $6.7 billion goodwill impairment, and the suspension of the company's aggressive buyback program.

The People Running This Company

Sarah London (CEO, age 45) became the youngest female CEO of a Fortune 500 company when she took the helm in March 2022, succeeding founder Michael Neidorff. Before Centene, she held roles at Optum (UnitedHealth Group), Humedica, and Accretive Health (now R1 RCM). She joined Centene in 2020 as EVP of Advanced Technology, was elevated to Vice Chairman in September 2021, then to CEO in March 2022. Her technology and healthcare analytics background is differentiated, but she inherited a company still digesting the massive WellCare acquisition and faced her most severe test in July 2025 when Centene withdrew its full-year guidance after an independent actuarial review revealed lower-than-expected enrollment and materially higher morbidity in Marketplace states. She bought 19,230 shares on the open market in August 2025 at approximately $25.50 per share – a credibility-positive signal during the crisis.

Drew Asher (CFO, age 57) joined in May 2021 from Arsenal Capital Partners and has overseen the company's Value Creation Plan, cost reductions, and $3 billion in buybacks in 2024. He is named as a defendant in the securities fraud class action.

Susan Smith (COO) and Christopher Koster (GC) round out the leadership team, with Koster providing state government affairs expertise as a former Missouri Attorney General.

What They Get Paid

CEO pay of $19.5 million in FY2025 is down 5% from $20.6 million in FY2024, a reasonable adjustment given the company posted a GAAP net loss of $6.7 billion (driven by a goodwill impairment) and withdrew full-year guidance mid-year. The CEO-to-median-employee pay ratio was 224x in FY2024. Non-equity incentive pay fell sharply from $4.3 million (FY2024) to $2.1 million (FY2025), reflecting the company's operational challenges. Relative to peers, CEO pay is in-line: Elevance Health's CEO earned $22.6 million and CVS Health's CEO earned $21.2 million in FY2025. Compensation is heavily weighted toward stock awards (~80% of total), aligning pay with shareholder outcomes over time. However, CFO Asher's total compensation jumped significantly to $16.1 million in FY2025 from $11.2 million in FY2024, driven by a near-doubling of stock awards – a questionable increase during a crisis year.

Are They Aligned?

Ownership and Control. CEO London directly owns approximately 845,275 shares (0.052% of shares outstanding). This is a modest holding for a Fortune 500 CEO. No single insider or family controls the company; it is widely held by institutions. Top institutional holders include AQR Capital Management (31.8 million shares), Arrowstreet Capital (8.6 million shares), Ameriprise Financial (7.1 million shares), and 8 Knots Management (4.7 million shares). ISS Governance QualityScore is 1 (best decile), indicating strong governance relative to peers.

Insider Buying and Selling. The most significant insider activity was CEO London's open-market purchase of 19,230 shares at ~$25.50 in August 2025, shortly after the stock collapsed 40% on the guidance withdrawal. Over the past 3 months, insiders have been net buyers of approximately $739,000 in shares. No open-market sales have been detected in recent months. The majority of Form 4 filings show tax-withholding dispositions upon vesting of restricted stock units, which are routine and not bearish signals.

Buybacks and Dilution. Centene was aggressively repurchasing shares – $3.0 billion in FY2024 (42.0 million shares) and $3.0 billion in FY2023. Shares outstanding declined from ~524 million (FY2023) to ~493 million (FY2025), a 5.9% reduction. However, the 2026 guidance includes no share buyback, signaling capital conservation during the operational reset. $2.2 billion remained authorized under the repurchase program as of early 2025.

Capital Allocation. The company signed a definitive agreement to divest remaining Magellan Health businesses in December 2025. In FY2025, Centene recorded a $6.7 billion goodwill impairment and $513 million Magellan impairment, pushing the company to a GAAP net loss of $6.7 billion. Total debt was $18.5 billion at year-end 2024. The halt of buybacks in 2026 is prudent given balance sheet pressures.

Securities Litigation. In July 2025, Centene abruptly withdrew its 2025 financial guidance after an independent actuarial review revealed that enrollment growth in 22 of 29 Marketplace states was lower than expected and morbidity was "materially inconsistent" with the company's earlier assumptions. The stock fell more than 40% in a single day (from $56.65 to $33.78). A class action lawsuit (Lunstrum v. Centene Corporation, No. 25-cv-05659, S.D.N.Y.) was filed alleging that the CEO and CFO made false and misleading statements about enrollment and morbidity between December 2024 and June 2025. The lead plaintiff deadline was September 8, 2025. The case is ongoing.

Skin-in-the-Game Score: 6 out of 10. CEO ownership is modest at 0.052% but the open-market purchase during the crisis was a positive signal. The company was a prolific buyer of its own stock ($6 billion in FY2023-2024) until the operational crisis forced a pause. No insider open-market sales have been detected. The securities lawsuit and guidance failure are the primary drags.

Board Quality

The board underwent a significant refresh between 2021 and 2023, with six new directors added and only one director (Eppinger) predating 2016. Seven of nine members are independent (78%). Only London and Burdick are non-independent – London as CEO, Burdick as a former Centene executive and former WellCare CEO. The addition of Kenneth Tanji (former Prudential Financial CFO) in February 2025 brought deep financial expertise. Thomas Greco resigned in August 2025 during the crisis, reducing the board from 10 to 9.

Strengths: Strong financial expertise (Blume from Deloitte, Coughlin from Tyco, Tanji from Prudential). Burdick provides deep Medicaid industry knowledge. The ISS QualityScore of 1 reflects strong governance structure.

Gaps: The board skews older (average age ~63) with only two female directors (22%). Healthcare provider/clinical expertise is underrepresented. The board lacks a dedicated technology/AI director despite Centene's data-centric strategy. The Greco resignation during the crisis period raises questions about boardroom dynamics.

Committee Structure: Four committees – Audit & Compliance (chaired by Tanji), Compensation & Talent (chaired by Coughlin), Governance (chaired by Samuels), and Quality (chaired by Burdick). London sits on no committees, which is standard for a CEO.

The Verdict

Strongest positives: Board independence is genuine (78%, ISS QualityScore of 1). Significant board refreshment since 2021. CEO made an open-market share purchase during the crisis. Aggressive buyback program ($6 billion in FY2023-2024) demonstrated shareholder return commitment before crisis. Compensation structure is heavily equity-weighted, aligning pay with stock performance.

Real concerns: The July 2025 guidance withdrawal and 40% single-day stock drop represent a credibility failure – either management did not know its own Marketplace fundamentals (competence issue) or knew and did not disclose (integrity issue). The securities class action names the CEO and CFO. A $6.7 billion goodwill impairment acknowledges value destruction. CFO compensation increased substantially in a year the company lost billions.

Upgrade catalyst: Successful resolution of the securities class action without material findings of fraud, combined with accurate guidance execution in FY2026, would restore management credibility and likely merit a B+ or higher.

Downgrade catalyst: Any finding of intentional misrepresentation in the class action, further insider selling, or a second guidance miss in FY2026 would push the grade to C+ or lower.